Oncotelic Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Oncotelic Therapeutics, Inc. (OTLC) reported Deferred Income Tax Expense (Benefit) of $111.60 million for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-13
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $111.60M 10-Q · filed 2026-08-13 | $111.55M 10-K · filed 2026-04-15 |